- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Imprime PGG, Pembrolizumab
- Biological · Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
- Interventions
- alemtuzumab, rituximab, PGG beta-glucan, flow cytometry, laboratory biomarker analysis, DNA analysis, fluorescence in situ hybridization, polymerase chain reaction, polymorphism analysis, mutation analysis
- Biological · Drug · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pancreatic Cancer
- Interventions
- BTH1704, IMPRIME PGG, Gemcitabine
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Interventions
- Imprime PGG, Pembrolizumab
- Biological
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- La Jolla, California • Whittier, California • New York, New York + 1 more
- Conditions
- Colorectal Cancer
- Interventions
- Imprime PGG + cetuximab, Cetuximab
- Biological · Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 44
- States / cities
- Florence, Alabama • Bentonville, Arkansas • Anaheim, California + 38 more
- Conditions
- Advanced Melanoma, Triple-Negative Breast Cancer
- Interventions
- Imprime PGG, Pembrolizumab
- Biological · Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Avondale, Arizona • Santa Monica, California • Aurora, Colorado + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Imprime PGG® Injection, Bevacizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Fayetteville, Arkansas • Canton, Ohio • San Antonio, Texas
- Conditions
- Colorectal Cancer
- Interventions
- Regorafenib, Atezolizumab, Imprime PGG, Bevacizumab, Isatuximab, Selicrelumab, Idasanutlin, AB928, LOAd703
- Drug · Genetic
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 2 more
- Conditions
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Interventions
- Imprime PGG, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Neoplasm of Breast
- Interventions
- Imprime PGG, Pembrolizumab
- Biological
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Denver, Colorado • Miami, Florida + 12 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- odetiglucan, CDX-1140
- Biological
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- NSCLC
- Interventions
- Imprime PGG Injection, Cetuximab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more
- Conditions
- Colorectal Cancer
- Interventions
- Imprime PGG
- Biological
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • New York, New York • Dallas, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Imprime PGG, MK-3475
- Drug
- Lead sponsor
- Lawrence Feldman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more